Analyst Insights - Digital Health Posts
Read our Analysts’ insights and expert opinions on the latest healthcare technology industry developments and market trends. Signify Research provides both free insights and premium insights which are only available to subscribers of "Signify Premium Insights".
Click on the premium insights link below to filter for just the premium content.
Signify Premium Insight: Butterfly Network and Caption Health Partner to Encourage Ultrasound Adoption
Signify Premium Insights Subscription Required
24th August 2021 – Butterfly Network’s recently announced partnership with Caption Health has the potential to overcome one of the biggest barriers facing handheld ultrasound. But, as this Premium Insight explores, there could also be some downsides to the deal.
Signify Premium Insight: HIMSS 2021: Steps not Step Changes
Signify Premium Insights Subscription Required
19th August 2021 – For many, HIMSS 2021 will have been the first in-person event they attended in almost two years. This Premium Insight details several announcements made at the conference and explores what they could mean for the Imaging IT market.
Nihon Kohden’s Acquisition of AMP3D Further Highlights Interest of Analytics in the Clinical World
19th August 2021 – On the 27th of July 2021, the US subsidiary of Nihon Kohden (Nihon Kohden Digital Health Solutions, Inc.) announced that it was to acquire 100% of the shares of US-based Advanced Medical Predictive Devices, Diagnostics and Displays, Inc. (“AMP3D”)
Signify Premium Insights: Zebra Acquisition Gives Nanox Chance to Earn its Stripes
Signify Premium Insights Subscription Required
17th August 2021 – Last week, upstart modality vendor Nanox announced it was acquiring AI developer Zebra Medical Vision and radiology service provider USARAD. An unexpected move, but, as this Premium Insight asks, is it a stroke of genius or an ill-considered plan?
Signify Premium Insight: A Study in Validation
Signify Premium Insights Subscription Required
13th August 2021 – The medical imaging AI market has been hindered by the lack of clinical validation studies. This is starting to change with several recent studies bolstering the market, while also offering a glimpse of what’s to come.